Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, ...
Mens Fitness on MSN
New FDA approval aims to help patients avoid bladder removal surgery
The decision gives certain patients whose cancer has resisted BCG therapy another treatment option aimed at preserving the ...
Morning Overview on MSN
The FDA approved Anktiva as the first treatment for one BCG-resistant form of bladder cancer
On October 14, the U.S. Food and Drug Administration announced that Anktiva (nogapendekin alfa inbakicept-pmln), used ...
American Society for Radiation Oncology (ASTRO) published its first clinical practice guideline on radiation therapy for ...
A retrospective study of 126 bladder cancer patients suggests that ERAS-based perioperative nursing care is associated with ...
FDA expands Anktiva approval for BCG-unresponsive bladder cancer. Learn about the 62% trial response, eligible patients, ...
ImmunityBio (IBRX) stock rises as FDA expands ANKTIVA approval to papillary-only bladder cancer, widening treatment access ...
An engineered ultrasound-responsive microrobot combining collagen-degrading bacteria, nanoparticles, and a targeted drug ...
Researchers at The University of Texas MD Anderson Cancer Center have developed a spatial map of muscle-invasive bladder cancer, revealing how tumor cell states, immune environments and therapeutic ...
In Part 1, I wrote about how cancers of the urinary tract present with the sign of "painless, yet intermittent" hematuria, and how that sign is easily overlooked. Today, I will talk about how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results